For the Inventor, By the Inventor

Enter assignee name

Seoul, South Korea

Enzychem Lifesciences Corporation

USPTO Granted Patents = 22

CIPO Patents = 7

EPO Patents = 14

Forward Citations = 7

Loading Chart...

Loading Chart...

45 inventors (with patents filed for the assignee):

Jae Wha Kim (12 out of 23 patents)

Ki Young Sohn (11 out of 11 patents)

Ki-Young Sohn (8 out of 8 patents)

4. Kyung Seop Ahn (7 out of 30 patents)

5. Yong-Hae Han (6 out of 6 patents)

6. Sei-Ryang Oh (5 out of 14 patents)

7. Tae-Suk Lee (5 out of 6 patents)

8. JongKoo Kang (4 out of 4 patents)

9. Ho Bum Kang (4 out of 7 patents)

10. Sun Young Yoon (4 out of 8 patents)

11. Jong Soo Lee (3 out of 34 patents)

12. Dae Myoung Yun (3 out of 3 patents)

13. Jong Koo Kang (3 out of 3 patents)

14. Tae Suk Lee (3 out of 3 patents)

15. Su Ui Lee (3 out of 6 patents)

22 patents: Sort by Forward Citations

1. 12297163 - Glycerol derivative, preparation method therefor, and immunomodulator comprising same as effective ingredient (2025-05-13),

2. 12187672 - 1,2-diacylglycerol compound, preparation method therefor, and immunomodulator containing same as active ingredient (2025-01-07),

3. 12076307 - Compositions for prevention or treatment of acute radiation syndrome and other radiation exposure (2024-09-03),

4. 11590096 - Compositions for prevention or treatment of acute radiation syndrome and other radiation exposure (2023-02-28),

5. 11491132 - Methods for treating thrombocytopenia (2022-11-08),

6. 11357749 - Methods for treating neutropenia (2022-06-14),

7. 11319294 - Method for manufacturing calteridol (2022-05-03),

8. 11192864 - Method for producing calcobutrol (2021-12-07),

9. 11135193 - Composition containing monoacetyldiacylglycerol compound as active ingredient for preventing or treating asthma (2021-10-05),

10. 11091449 - Gadobutrol intermediate and gadobutrol production method using same (2021-08-17),

11. 10857119 - Composition containing monoacetyldiacylglycerol compound as active ingredient for inhibiting blood cancer or metastasis (2020-12-08),

12. 10765655 - Composition containing monoacetyldiglyceride compound as active ingredient for preventing or treating chronic obstructive pulmonary disease (2020-09-08),

13. 10653657 - Method for treating hemolytic uremic syndrome (2020-05-19),

14. 10596141 - Methods for treating thrombocytopenia (2020-03-24),

15. 10588886 - Methods for treating neutropenia (2020-03-17),

Enzychem Lifesciences Corporation is a global biopharmaceutical company that specializes in the development and commercialization of innovative therapeutics. With a focus on finding solutions for unmet medical needs, Enzychem is dedicated to improving human health through cutting-edge research, development, and manufacturing. The company's unique platform technology allows for the discovery and production of next-generation biologics, offering promising treatment options in areas such as oncology, autoimmune diseases, and infectious diseases.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 23 2025

22 Patents

#176 in Seoul

#576 in South Korea

#27,885 in the World

Seoul, South Korea

Enzychem Lifesciences Corporation

Forward Citations = 7

45 inventors:

Jae Wha Kim (12 out of 23 patents)

Ki Young Sohn (11 out of 11 patents)

Ki-Young Sohn (8 out of 8 patents)

4. Kyung Seop Ahn (7 out of 30 patents)

5. Yong-Hae Han (6 out of 6 patents)

Please report any incorrect information to support@idiyas.com

Loading…